1
Home
Companies

Cyclo Therapeutics

Cyclo Therapeutics
Leadership team

Mr. N. Scott Fine (CEO & Director)

Mr. C. E Strattan (Founder & Director)

Mr. Michael Eric Lisjak (Chief Regulatory Officer & Sr. VP of Bus. Devel.)

Products/ Services
Biotechnology, Health Care, Health Diagnostics, Pharmaceutical
Number of Employees
0 - 50
Headquarters
Alachua, Florida, United States
Established
1990
Company Registration
SEC CIK number: 0000922247
Revenue
500K - 2M
Traded as
OTCQB:CTDH
Social Media
URL
https://www.cyclotherapeutics.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
History

Cyclo Therapeutics was founded in 2017 by a team of dedicated scientists and clinical researchers. Since our founding, we have focused on finding novel solutions to provide novel therapies for patients suffering from a wide range of inflammatory conditions, including but not limited to, Alzheimers, Crohn’s Disease, Multiple Sclerosis, and Rheumatoid Arthritis.

Mission
Our mission is to provide patient-specific treatments and improve current standards of care for diseases with unmet medical needs.
Vision
Our vision is to be a global leader in innovative research and development of personalized therapies for patients suffering from inflammatory and neurological diseases.
Key Team

Mr. Joshua M. Fine (CFO & Sec.)

Dr. Jeffrey L. Tate Ph.D. (COO, Chief Quality Officer & Director)

Mr. George L. Fails (Exec. VP and Operations Mang.)

Ms. Lori McKenna Gorski (Global Head of Patient Advocacy)

Dr. Lise Lund Kjems M.D., Ph.D. (Chief Medical Officer)

Recognition and Awards
Cyclo Therapeutics has received a number of awards, including the coveted Golden Lion Award for Innovation from the British Biotech Association and the Breakthrough Technology Award from the American Society for Biochemistry and Molecular Biology. Additionally, Cyclo Therapeutics has been recognized by Fast Company for its commitment to medical research and advancement.
References

https://in.investing.com/equities/ctd-holdings-inc

https://finance.yahoo.com/quote/CYTH/profile?p=CYTH

https://www.crunchbase.com/organization/ctd-holdings

https://www.cyclotherapeutics.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Cyclo Therapeutics
Leadership team

Mr. N. Scott Fine (CEO & Director)

Mr. C. E Strattan (Founder & Director)

Mr. Michael Eric Lisjak (Chief Regulatory Officer & Sr. VP of Bus. Devel.)

Products/ Services
Biotechnology, Health Care, Health Diagnostics, Pharmaceutical
Number of Employees
0 - 50
Headquarters
Alachua, Florida, United States
Established
1990
Company Registration
SEC CIK number: 0000922247
Revenue
500K - 2M
Traded as
OTCQB:CTDH
Social Media
URL
https://www.cyclotherapeutics.com